These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 34046161)

  • 21. SARS-CoV-2 Spike Protein Destabilizes Microvascular Homeostasis.
    Panigrahi S; Goswami T; Ferrari B; Antonelli CJ; Bazdar DA; Gilmore H; Freeman ML; Lederman MM; Sieg SF
    Microbiol Spectr; 2021 Dec; 9(3):e0073521. PubMed ID: 34935423
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monoclonal antibody therapy in COVID-19.
    Conti P; Pregliasco FE; Calvisi V; Caraffa Al; Gallenga CE; Kritas SK; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(2):423-427. PubMed ID: 33904269
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Complement Activation
    Niederreiter J; Eck C; Ries T; Hartmann A; Märkl B; Büttner-Herold M; Amann K; Daniel C
    Front Immunol; 2022; 13():835156. PubMed ID: 35237273
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 25. How the Innate Immune System of the Blood Contributes to Systemic Pathology in COVID-19-Induced ARDS and Provides Potential Targets for Treatment.
    Nilsson B; Persson B; Eriksson O; Fromell K; Hultström M; Frithiof R; Lipcsey M; Huber-Lang M; Ekdahl KN
    Front Immunol; 2022; 13():840137. PubMed ID: 35350780
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Coronavirus-19 (SARS-CoV-2) induces acute severe lung inflammation via IL-1 causing cytokine storm in COVID-19: a promising inhibitory strategy.
    Conti P; Caraffa A; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Ronconi G
    J Biol Regul Homeost Agents; 2020; 34(6):1971-1975. PubMed ID: 33016027
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pathogenesis-directed therapy of 2019 novel coronavirus disease.
    Stratton CW; Tang YW; Lu H
    J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The coagulopathy, endotheliopathy, and vasculitis of COVID-19.
    Iba T; Connors JM; Levy JH
    Inflamm Res; 2020 Dec; 69(12):1181-1189. PubMed ID: 32918567
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Innate immunity during SARS-CoV-2: evasion strategies and activation trigger hypoxia and vascular damage.
    Amor S; Fernández Blanco L; Baker D
    Clin Exp Immunol; 2020 Nov; 202(2):193-209. PubMed ID: 32978971
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Central nervous system complications associated with SARS-CoV-2 infection: integrative concepts of pathophysiology and case reports.
    Najjar S; Najjar A; Chong DJ; Pramanik BK; Kirsch C; Kuzniecky RI; Pacia SV; Azhar S
    J Neuroinflammation; 2020 Aug; 17(1):231. PubMed ID: 32758257
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
    Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
    Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 33. COVID-19 Sepsis: Pathogenesis and Endothelial Molecular Mechanisms Based on "Two-Path Unifying Theory" of Hemostasis and Endotheliopathy-Associated Vascular Microthrombotic Disease, and Proposed Therapeutic Approach with Antimicrothrombotic Therapy.
    Chang JC
    Vasc Health Risk Manag; 2021; 17():273-298. PubMed ID: 34103921
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neurovascular injury with complement activation and inflammation in COVID-19.
    Lee MH; Perl DP; Steiner J; Pasternack N; Li W; Maric D; Safavi F; Horkayne-Szakaly I; Jones R; Stram MN; Moncur JT; Hefti M; Folkerth RD; Nath A
    Brain; 2022 Jul; 145(7):2555-2568. PubMed ID: 35788639
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is the COVID-19 thrombotic catastrophe complement-connected?
    Conway EM; Pryzdial ELG
    J Thromb Haemost; 2020 Nov; 18(11):2812-2822. PubMed ID: 32762081
    [TBL] [Abstract][Full Text] [Related]  

  • 36. COVID-19 and Toll-Like Receptor 4 (TLR4): SARS-CoV-2 May Bind and Activate TLR4 to Increase ACE2 Expression, Facilitating Entry and Causing Hyperinflammation.
    Aboudounya MM; Heads RJ
    Mediators Inflamm; 2021; 2021():8874339. PubMed ID: 33505220
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting the Complement-Sphingolipid System in COVID-19 and Gaucher Diseases: Evidence for a New Treatment Strategy.
    Trivedi VS; Magnusen AF; Rani R; Marsili L; Slavotinek AM; Prows DR; Hopkin RJ; McKay MA; Pandey MK
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430817
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impaired coagulation, liver dysfunction and COVID-19: Discovering an intriguing relationship.
    D'Ardes D; Boccatonda A; Cocco G; Fabiani S; Rossi I; Bucci M; Guagnano MT; Schiavone C; Cipollone F
    World J Gastroenterol; 2022 Mar; 28(11):1102-1112. PubMed ID: 35431501
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of Epithelial-Endothelial Cell Interaction in the Pathogenesis of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection.
    Hui KP; Cheung MC; Lai KL; Ng KC; Ho JC; Peiris M; Nicholls JM; Chan MC
    Clin Infect Dis; 2022 Jan; 74(2):199-209. PubMed ID: 33956935
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Coagulopathy, endothelial dysfunction, thrombotic microangiopathy and complement activation: potential role of complement system inhibition in COVID-19.
    Wang X; Sahu KK; Cerny J
    J Thromb Thrombolysis; 2021 Apr; 51(3):657-662. PubMed ID: 33063256
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.